Advisors Preferred’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Advisors Preferred's NBIX Position: Q2 2026 in Review
Advisors Preferred opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 31,074 shares worth $5.41M. The stake represents 0.84% of the portfolio and ranks #38 among its holdings. This is a return to the name: Advisors Preferred previously reported a position in NBIX as recently as Q4 2025.
Advisors Preferred first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Advisors Preferred held 31,074 shares of Neurocrine Biosciences worth $5.41M as of Q2 2026.
- Neurocrine Biosciences was a new Advisors Preferred position in Q2 2026.
- Neurocrine Biosciences made up 0.84% of Advisors Preferred's portfolio in Q2 2026, its #38 holding.
- Advisors Preferred first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
- 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Advisors Preferred's 13F filing for Q2 2026, filed 11 Aug 2026.